This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wiles, N Articles by Hunt, B J Search for Related Content PubMed PubMed Citation Articles by Wiles, N Articles by Hunt, B J Social Bookmarking                   What's this?

Anticoagulation via anti-Factor Xa inhibition

Departments of Haematology and Lupus Unit, Guy’s & St Thomas’ NHS Foundation Trust, London, UK

B J Hunt

Departments of Haematology and Lupus Unit, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, beverley.hunt{at}gstt.nhs.uk

Hospital-acquired deep vein thrombosis (DVT) affects 10-25% of medical patients and up to 60% of surgical patients. While thromboprophylaxis is without a doubt under utilized in the hospital setting, there is also a need for more efficacious agents. Fondaparinux, the first of a new class of agents Factor Xa inhibitiors, has recently come into clinical use. It is a synthetic pentasaccharide and indirect Factor Xa inhibitor with a predictable antithrombotic action. Being a synthetic product, there are no concerns about supply, nor viral or prion protein contamination. Initial large international trials in orthopaedic patients demonstrated its superior efficacy to standard thromboprophylaxis. Further trials confirmed its superior efficacy in venous thromboembolism (VTE) prevention, both in medical and surgical patient groups, as well as treatment of pulmonary embolism and DVT. Its use has also recently been evaluated in acute coronary syndromes and angioplasty. Fondaparinux currently has licenses in the UK for thromboprophylaxis and treatment of VTE and a license for the management of acute coronary syndrome is likely to be forthcoming. It has a favourable side effect profile and if the price is acceptable, is likely to take over from low molecular weight heparins in these indications as the drug of choice on the grounds of efficacy and safety.

Key Words: anticoagulation • factor Xa inhibition • fondaparinux • thromboprophylaxis

Lupus, Vol. 15, No. 3, 167-171 (2006)
DOI: 10.1191/0961203306lu2275rr


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Rawat, T. T. Huynh, E. K. Peden, P. Kougias, and P. H. Lin Primary Prophylaxis of Venous Thromboembolism in Surgical Patients Vascular and Endovascular Surgery, June 1, 2008; 42(3): 205 - 216. [Abstract] [PDF]